Global Patent Index - EP 3506899 A4

EP 3506899 A4 20200520 - COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF LYMPHATIC SYSTEM DISORDERS

Title (en)

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF LYMPHATIC SYSTEM DISORDERS

Title (de)

ZUSAMMENSETZUNG UND VERFAHREN ZUR DIAGNOSE UND BEHANDLUNG VON ERKRANKUNGEN DES LYMPHATISCHEN SYSTEMS

Title (fr)

COMPOSITIONS ET MÉTHODES DE DIAGNOSTIC ET DE TRAITEMENT DE TROUBLES DU SYSTÈME LYMPHATIQUE

Publication

EP 3506899 A4 20200520 (EN)

Application

EP 17847498 A 20170830

Priority

  • US 201662382147 P 20160831
  • US 2017049453 W 20170830

Abstract (en)

[origin: WO2018045078A2] Compositions and methods for the diagnosis and treatment of lymphatic anomaly are disclosed.

IPC 8 full level

C12Q 1/6883 (2018.01); A61K 31/395 (2006.01); A61K 31/436 (2006.01); G01N 33/48 (2006.01)

CPC (source: EP US)

A61K 31/4184 (2013.01 - US); A61K 31/436 (2013.01 - EP US); A61K 31/4427 (2013.01 - US); A61K 31/4709 (2013.01 - US); A61K 31/501 (2013.01 - US); A61K 31/519 (2013.01 - EP US); A61K 31/5377 (2013.01 - US); A61K 45/06 (2013.01 - EP); A61P 7/00 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 43/00 (2018.01 - EP US); C12Q 1/6883 (2013.01 - EP US); A61K 45/06 (2013.01 - US); C12Q 2600/156 (2013.01 - EP US)

C-Set (source: EP)

  1. A61K 31/519 + A61K 2300/00
  2. A61K 31/436 + A61K 2300/00

Citation (search report)

  • [I] LI ET AL: "Whole Exome Sequencing Identifies EPHB4 As A Novel Cause Of Autosomal Dominant Lymphangiomatosis", 2015 ACMG ANNUAL CLINICAL GENETICS MEETING; SALT LAKE CITY, UTAH, USA; MARCH 24-28, 2015, ACMG, US, 28 February 2015 (2015-02-28), pages 1 - 2, XP009518754
  • [I] SILVIA MARTIN-ALMEDINA ET AL: "EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis", JOURNAL OF CLINICAL INVESTIGATION, vol. 126, no. 8, 11 July 2016 (2016-07-11), GB, pages 3080 - 3088, XP055684076, ISSN: 0021-9738, DOI: 10.1172/JCI85794
  • [I] KIERSTEN W RICCI ET AL: "A5454: A Phase 2 Clinical Trial Assessing Efficacy And Safety Of The Mtor Inhibitor Sirolimus In The Treatment Of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, And Gorham-Stout Disease", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE; AMERICAN THORACIC SOCIETY 2015 INTERNATIONAL CONFERENCE, D23. PEDIATRIC RARE DISEASES AND LUNG DEVELOPMENT, AMERICAN THORACIC SOCIETY, UNITED STATES; DENVER, CO, USA, vol. 191, no. Suppl, 1 January 2015 (2015-01-01), pages A5454, XP009515309, ISSN: 1535-4970, DOI: 10.1164/AJRCCM-CONFERENCE.2015.191.1_MEETINGABSTRACTS.A5454
  • [A] D. M. ADAMS ET AL: "Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies", PEDIATRICS, vol. 137, no. 2, 1 February 2016 (2016-02-01), US, pages 1 - 10, XP055594791, ISSN: 0031-4005, DOI: 10.1542/peds.2015-3257
  • [T] DONG LI ET AL: "Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly", HUMAN MOLECULAR GENETICS, vol. 27, no. 18, 14 June 2018 (2018-06-14), pages 3233 - 3245, XP055684131, ISSN: 0964-6906, DOI: 10.1093/hmg/ddy218
  • [T] LI DONG ET AL: "recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor", NATURE MEDICINE, NATURE PUB. CO, NEW YORK, vol. 25, no. 7, 1 July 2019 (2019-07-01), pages 1116 - 1122, XP036928340, ISSN: 1078-8956, [retrieved on 20190701], DOI: 10.1038/S41591-019-0479-2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2018045078 A2 20180308; WO 2018045078 A3 20190425; AU 2017319507 A1 20190314; AU 2017319507 B2 20231123; AU 2024201122 A1 20240314; CA 3034786 A1 20180308; DK 3506899 T3 20220307; EP 3506899 A2 20190710; EP 3506899 A4 20200520; EP 3506899 B1 20211215; EP 4023769 A1 20220706; ES 2906333 T3 20220418; JP 2019533987 A 20191128; JP 2023052057 A 20230411; JP 7202287 B2 20230111; US 11401553 B2 20220802; US 2020056238 A1 20200220; US 2023048706 A1 20230216

DOCDB simple family (application)

US 2017049453 W 20170830; AU 2017319507 A 20170830; AU 2024201122 A 20240221; CA 3034786 A 20170830; DK 17847498 T 20170830; EP 17847498 A 20170830; EP 21214113 A 20170830; ES 17847498 T 20170830; JP 2019511562 A 20170830; JP 2022206535 A 20221223; US 201716327060 A 20170830; US 202217815647 A 20220728